US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyntra Bio Inc

7.52

+0.20002.73%

Volume:40.01K

Turnover:298.12K

Market Cap:30.42M

PE:0.17

High:7.60

Open:7.35

Low:7.30

Close:7.32

52wk High:12.60

52wk Low:6.32

Shares:4.05M

Float Shares:3.56M

Volume Ratio:2.00

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):45.27

EPS(LYR):45.37

ROE:--

ROA:-22.50%

PB:-1.01

PE(LYR):0.17

Loading ...

Overview Company News Filings

Kyntra Bio Inc. publishes corporate presentation on FG-3246 and roxadustat after USD 220 million FibroGen China sale

Kyntra Bio Publishes Corporate Presentation on Prostate Cancer Programs FG-3246 and FG-3180 and Roxadustat in LR-MDS Anemia

What's Going On With Kyntra Bio Stock Tuesday?

Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Kyntra Bio (KYNB) and Hims & Hers Health (HIMS)

Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246

Kyntra Bio reports positive Phase 1b/2 data for FG-3246 plus enzalutamide in mCRPC

Kyntra Bio Announces Positive Data From the Investigator-Sponsored Phase 1B/2 Study of FG-3246 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer to Be Presented at Asco Gu 2026

THOMSON REUTERS

Kyntra Bio to Present at Oppenheimer and Leerink Healthcare Conferences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/KYNB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KYNB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","market":"US","secType":"STK","nameCN":"Kyntra Bio Inc","latestPrice":7.52,"timestamp":1787342400000,"preClose":7.32,"halted":0,"volume":40008,"delay":0,"changeRate":0.0273224043715846,"floatShares":3561200,"shares":4045445,"eps":45.266125,"marketStatus":"Pre-Mkt","change":0.2,"latestTime":"08-24 08:30:24 EDT","open":7.35,"high":7.6,"low":7.3,"amount":298122.972672,"amplitude":0.040984,"askPrice":8.35,"askSize":100,"bidPrice":7.53,"bidSize":1,"shortable":3,"etf":0,"ttmEps":45.266125,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":7.52,"postHourTrading":{"tag":"盘后","latestPrice":7.52,"preClose":7.52,"latestTime":"19:30 EDT","volume":60,"amount":458.4146,"timestamp":1787355005170,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.000600063007201},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYNB\",,,,,undefined,":{"symbol":"KYNB","floatShares":3561200,"roa":"-22.50%","roe":"--","lyrEps":45.371456,"volumeRatio":2.000600063007201,"shares":4045445,"dividePrice":0,"high":7.6,"amplitude":0.040984,"preClose":7.32,"low":7.3,"week52Low":6.32,"pbRate":"-1.01","psRate":"6.59","week52High":12.6,"institutionHeld":0,"latestPrice":7.52,"committee":-0.980198,"eps":45.266125,"divideRate":0,"volume":40008,"delay":0,"ttmEps":45.266125,"open":7.35,"prevYearClose":8.78,"prevWeekClose":7.52,"prevMonthClose":6.73,"prevQuarterClose":7.55,"fiveDayClose":7.05,"twentyDayClose":7.03,"sixtyDayClose":7.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYNB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"KYNB","fiscalQuarterEnding":"2026/06","expectedEps":-3.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-4.68},{"market":"US","date":"2026-05-11","symbol":"KYNB","fiscalQuarterEnding":"2026/03","expectedEps":-3.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-3.74},{"market":"US","date":"2026-03-16","symbol":"KYNB","fiscalQuarterEnding":"2025/12","expectedEps":-3.89,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"post","actualEps":-3.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYNB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYNB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1783396800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYNB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYNB","date":"2026-08-21","current":0.166129,"percent":0.487013,"low":0.128311,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"high":0.188779,"avg":0.161409,"sd":0.014739,"marketCap":29639587},"quantilePoints":[{"date":"2026-01-09","current":0.17821,"twenty":0.178998,"median":0.18018,"eighty":0.181362,"marketCap":38431727},{"date":"2026-01-16","current":0.170144,"twenty":0.170369,"median":0.172958,"eighty":0.17821,"marketCap":36692186},{"date":"2026-01-23","current":0.168268,"twenty":0.168268,"median":0.171269,"eighty":0.17821,"marketCap":36287641},{"date":"2026-01-30","current":0.150259,"twenty":0.160389,"median":0.169206,"eighty":0.172958,"marketCap":32404014},{"date":"2026-02-06","current":0.140692,"twenty":0.153073,"median":0.163953,"eighty":0.171457,"marketCap":30340837},{"date":"2026-02-13","current":0.140317,"twenty":0.147445,"median":0.160201,"eighty":0.171269,"marketCap":30259928},{"date":"2026-02-20","current":0.14707,"twenty":0.146282,"median":0.158795,"eighty":0.170369,"marketCap":31716288},{"date":"2026-02-27","current":0.13075,"twenty":0.144894,"median":0.154199,"eighty":0.170144,"marketCap":28196751},{"date":"2026-03-06","current":0.129155,"twenty":0.137315,"median":0.150635,"eighty":0.168643,"marketCap":27852888},{"date":"2026-03-13","current":0.131688,"twenty":0.133714,"median":0.147445,"eighty":0.165191,"marketCap":28399023},{"date":"2026-03-20","current":0.161033,"twenty":0.133301,"median":0.147633,"eighty":0.164047,"marketCap":29541837},{"date":"2026-03-27","current":0.144268,"twenty":0.133714,"median":0.1489,"eighty":0.163953,"marketCap":26466248},{"date":"2026-04-02","current":0.156621,"twenty":0.135327,"median":0.1489,"eighty":0.163094,"marketCap":28732471},{"date":"2026-04-10","current":0.158607,"twenty":0.13649,"median":0.150021,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-17","current":0.158607,"twenty":0.137128,"median":0.152651,"eighty":0.161629,"marketCap":29096686},{"date":"2026-04-24","current":0.154658,"twenty":0.137616,"median":0.154087,"eighty":0.16165,"marketCap":28372304},{"date":"2026-05-01","current":0.160371,"twenty":0.138929,"median":0.154658,"eighty":0.161209,"marketCap":29420432},{"date":"2026-05-08","current":0.156671,"twenty":0.140092,"median":0.155492,"eighty":0.161033,"marketCap":28741595},{"date":"2026-05-15","current":0.173439,"twenty":0.140542,"median":0.155518,"eighty":0.16165,"marketCap":28377265},{"date":"2026-05-22","current":0.171707,"twenty":0.141779,"median":0.155761,"eighty":0.163953,"marketCap":28093897},{"date":"2026-05-29","current":0.173687,"twenty":0.143209,"median":0.156128,"eighty":0.168258,"marketCap":28417746},{"date":"2026-06-05","current":0.168491,"twenty":0.144709,"median":0.156621,"eighty":0.168887,"marketCap":27567642},{"date":"2026-06-12","current":0.167254,"twenty":0.145601,"median":0.156867,"eighty":0.168639,"marketCap":27365237},{"date":"2026-06-18","current":0.170965,"twenty":0.145982,"median":0.157197,"eighty":0.169431,"marketCap":27972453},{"date":"2026-06-26","current":0.171707,"twenty":0.14617,"median":0.158138,"eighty":0.170144,"marketCap":28093897},{"date":"2026-07-02","current":0.1868,"twenty":0.14632,"median":0.158607,"eighty":0.170718,"marketCap":30563245},{"date":"2026-07-10","current":0.181109,"twenty":0.146883,"median":0.158743,"eighty":0.171457,"marketCap":29632179},{"date":"2026-07-17","current":0.182841,"twenty":0.14707,"median":0.160014,"eighty":0.171955,"marketCap":29915547},{"date":"2026-07-24","current":0.174924,"twenty":0.147445,"median":0.160711,"eighty":0.173192,"marketCap":28620151},{"date":"2026-07-31","current":0.167996,"twenty":0.147746,"median":0.161253,"eighty":0.173241,"marketCap":27486680},{"date":"2026-08-07","current":0.172709,"twenty":0.148684,"median":0.162522,"eighty":0.173005,"marketCap":28257845},{"date":"2026-08-14","current":0.174182,"twenty":0.14943,"median":0.163953,"eighty":0.173489,"marketCap":28498708},{"date":"2026-08-21","current":0.161795,"twenty":0.149739,"median":0.162522,"eighty":0.173439,"marketCap":29639587}],"updateTime":1787565966232},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYNB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618947240","title":"Kyntra Bio Inc. publishes corporate presentation on FG-3246 and roxadustat after USD 220 million FibroGen China sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947240","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947240?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:56","pubTimestamp":1773233784,"startTime":"0","endTime":"0","summary":"Kyntra Bio said it completed the sale of FibroGen China to AstraZeneca for approximately USD 220 million. The company said it repaid a term loan to Morgan Stanley Tactical Value and extended its cash runway into 2028. Kyntra Bio said its Phase 2 monotherapy trial of FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer is enrolling, with interim results expected in 2H 2026. The presentation said FG-3246 is a CD46-targeting antibody-drug conjugate and FG-3180 is a PET imaging agent being developed as a patient selection biomarker.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on March 11, 2026, and is solely responsible for the information ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL9y31nt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","03165","LU0496365809.HKD","LU0526926950.USD","LU1983299246.USD","LU0784385840.USD","AZN.UK","LU0557290698.USD","LU1023059063.AUD","LU0211326755.USD","LU0738911758.USD","LU0784384876.USD","LU1267930813.SGD","LU0920840948.USD","SG9999001176.SGD","LU0882574055.USD","LU0827474353.SGD","LU0575583348.USD","LU1084165304.USD","LU1170363599.USD","LU0310799852.SGD","LU1104425308.USD","LU1291159041.SGD","LU0887340254.USD","LU1989772923.USD","LU0949170772.SGD","LU2091194634.USD","LU0047473722.SGD","IE00BKPKM643.USD","LU0553294199.USD","LU1057294990.SGD","LU0128525929.USD","LU2279689827.SGD","LU0011850046.USD","LU0266013472.USD","LU0964806797.USD","LU0997586432.USD","LU1301847155.USD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU0976567544.SGD","LU0972486137.USD","BK4139","LU2114397693.USD","LU1880407215.USD","LU1989771016.USD","KYNB","IE00BFTCPJ56.SGD","LU1261432733.SGD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614029417","title":"Kyntra Bio Publishes Corporate Presentation on Prostate Cancer Programs FG-3246 and FG-3180 and Roxadustat in LR-MDS Anemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029417","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614029417?lang=en_us&edition=fundamental","pubTime":"2026-02-27 00:26","pubTimestamp":1772123216,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc. released a corporate presentation outlining its oncology and hematology pipeline. The company highlighted FG-3246, a CD46-targeting antibody-drug conjugate, and FG-3180, a PET imaging agent being evaluated as a potential patient selection biomarker in metastatic castration-resistant prostate cancer. Kyntra Bio said a Phase 2 monotherapy trial in post-ARPI, pre-chemotherapy mCRPC is enrolling, with interim data expected in the second half of 2026. The presentation also described roxadustat as a Phase 3-ready U.S. development opportunity in anemia due to low-risk myelodysplastic syndromes, noting FDA alignment on key Phase 3 trial design elements and Orphan Drug Designation granted in December 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL975yt2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613748578","title":"What's Going On With Kyntra Bio Stock Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2613748578","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613748578?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:27","pubTimestamp":1771939620,"startTime":"0","endTime":"0","summary":"Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/24/Genetic-Research-And-Biotech-Science-Con_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/24/Genetic-Research-And-Biotech-Science-Con_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50812020/whats-going-on-with-kyntra-bio-stock-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50812020/whats-going-on-with-kyntra-bio-stock-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613796488","title":"Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Kyntra Bio (KYNB) and Hims & Hers Health (HIMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613796488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613796488?lang=en_us&edition=fundamental","pubTime":"2026-02-24 16:50","pubTimestamp":1771923012,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Brookdale Senior Living (BKD – Research Report), K...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-brookdale-senior-living-bkd-kyntra-bio-kynb-and-hims-hers-health-hims-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-brookdale-senior-living-bkd-kyntra-bio-kynb-and-hims-hers-health-hims-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU0128526141.USD","XBI","BK4137","BK4196","HIYY","LU2190626999.HKD","LABU","BK4185","BK4139","HIMZ","BK4581","BK4585","BK4588","BKD","LU1499592464.USD","HMYY","HIMY","HIMS","KYNB","LU0842063009.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613500753","title":"Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246","url":"https://stock-news.laohu8.com/highlight/detail?id=2613500753","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613500753?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:16","pubTimestamp":1771884968,"startTime":"0","endTime":"0","summary":"The company states: “Kyntra Bio (KYNB), formerly FibroGen (FGEN), announced that the data on anti-tumor activity of FG-3246 in combination with enz...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyntra-bio-announces-positive-data-from-phase-1b-2-study-of-fg-3246-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyntra-bio-announces-positive-data-from-phase-1b-2-study-of-fg-3246-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYNB","BK4162","FG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613580117","title":"Kyntra Bio reports positive Phase 1b/2 data for FG-3246 plus enzalutamide in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2613580117","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613580117?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:10","pubTimestamp":1771884615,"startTime":"0","endTime":"0","summary":"Kyntra Bio Inc. announced positive data from an investigator-sponsored Phase 1b/2 study evaluating FG-3246  in combination with enzalutamide in biomarker-unselected, ARPI-treated, taxane-nave patients with metastatic castration-resistant prostate cancer. In 44 patients, the combination produced a median radiographic progression-free survival of 7.0 months overall and 10.1 months in patients who had progressed on only one prior ARPI, with a composite response rate of 21% overall and 40% in the one-prior-ARPI subgroup. The company said these results will be presented at the ASCO GU 2026 meeting on February 26, 2026, and noted that FG-3246 is also being studied in a Phase 2 monotherapy trial with an interim analysis planned for the second half of 2026, incorporating baseline FG-3180 CD46-directed PET imaging to assess potential patient selection.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL8N11ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4112","IE00BKPKM429.USD","BK4139","LU2210149790.SGD","NDAQ","KYNB","SG9999014013.SGD","BK4585","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613758053","title":"Kyntra Bio Announces Positive Data From the Investigator-Sponsored Phase 1B/2 Study of FG-3246 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer to Be Presented at Asco Gu 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613758053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613758053?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:10","pubTimestamp":1771884600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nTUABYCS02:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612460571","title":"Kyntra Bio to Present at Oppenheimer and Leerink Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612460571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612460571?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:05","pubTimestamp":1771362323,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL86fzdC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4139","KYNB","NDAQ","IE00BGHQF748.EUR","BK4588","LU2210149790.SGD","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":48,"code":"91000000","status":"200"}]}}